USPH Price To Sales Ratio from 2010 to 2024
| USPH Stock | USD 96.94 2.88 3.06% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 2.18496354 | Current Value 2.99 | Quarterly Volatility 6.21958445 |
Check US Physicalrapy financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among US Physicalrapy's main balance sheet or income statement drivers, such as Interest Expense of 9.8 M, Total Revenue of 635 M or Gross Profit of 117.6 M, as well as many indicators such as Price To Sales Ratio of 2.99, Dividend Yield of 0.0194 or PTB Ratio of 4.71. USPH financial statements analysis is a perfect complement when working with US Physicalrapy Valuation or Volatility modules.
USPH | Price To Sales Ratio |
Latest US Physicalrapy's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of US Physicalrapy over the last few years. Price to Sales Ratio is figured by comparing US Physicalrapy stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on US Physicalrapy sales, a figure that is much harder to manipulate than other US Physicalrapy multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. US Physicalrapy's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in US Physicalrapy's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.29 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
USPH Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 3.83 | |
| Geometric Mean | 2.50 | |
| Coefficient Of Variation | 162.28 | |
| Mean Deviation | 2.98 | |
| Median | 2.19 | |
| Standard Deviation | 6.22 | |
| Sample Variance | 38.68 | |
| Range | 25.1877 | |
| R-Value | (0.36) | |
| Mean Square Error | 36.27 | |
| R-Squared | 0.13 | |
| Significance | 0.19 | |
| Slope | (0.50) | |
| Total Sum of Squares | 541.57 |
USPH Price To Sales Ratio History
About US Physicalrapy Financial Statements
Investors use fundamental indicators, such as US Physicalrapy's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although US Physicalrapy's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 2.18 | 2.99 |
Currently Active Assets on Macroaxis
When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:Check out the analysis of US Physicalrapy Correlation against competitors. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.24) | Dividend Share 1.75 | Earnings Share 0.88 | Revenue Per Share 42.489 | Quarterly Revenue Growth 0.12 |
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.